A Study to See if a Combination of Vitamins That is Injected Into a Muscle is as Good and Safe as a Vitamin That is Taken by Mouth

NCT07029698 | Recruiting Phase 4

• 1 other identifier: 6630-4200-42
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 2

Brief Summary

Primary efficacy objective: To investigate the effects of a parenterally vitamin B12 combination treatment versus an oral vitamin B12 mono therapy on the vitamin B12 status in female and male patients as determined by the change from baseline in serum vitamin B12 concentration after 4 weeks (28 days) of treatment. Secondary efficacy objectives: To evaluate the effects of a parenterally vitamin B12 combination versus an oral vitamin B12 mono therapy after 4 weeks of treatment on:

• Serum holotranscobalamin
• Serum homocysteine
• Serum methylmalonic acid
• Combined vitamin B12 markers (cB12)
• Serum folic acid
• Serum vitamin B6
• Serum S-adenosylmethione (SAM)
• Serum S-adenosylhomocysteine (SAH)
• SAM/SAH ratio
• WHO-5 Well-Being Index
• Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36)
• Visual analogue scale (VAS) EQ-5D. Safety objectives: To evaluate the safety and tolerability of oral vitamin B12 mono therapy versus intramuscular vitamin B12 combination.

Conditions

Vitamin B12 Deficiency

Keywords

Vitamin B12 deficiency; Vitamin B12 status; methylation capacity; holotranscobalamin; homocysteine; methylmalonic acid; folic acid; vitamin B6; S-adenosylmethione; S-adenosylhomocysteine

Outcome Measures

Primary Outcomes (1)

• Vitamin B12

  Effects of treatment on serum vitamin B12

  Change from baseline at day 28

Secondary Outcomes (10)

• Holotranscobalamin

  Change from baseline at day 28 and at follow up at day 56

• Homocystein

  Change from baseline at day 28 and at follow up at day 56

• Methylmalonic acid

  Change from baseline at day 28 and at follow up at day 56

• Combined vitamin B12 marker (cB12)

  Change from baseline at day 28 and at follow up at day 56

• Serum S-adenosylmethione (SAM)

  Change from baseline at day 28 and at follow up at day 56

Other Outcomes (1)

• Safety objectives

  assessed through 56 days of patient's participation

Study Arms (2)

Vitamin injection

EXPERIMENTAL

1 injection twice weekly at the clinical site. Totally 8 injections through 4 week treatment period

Drug: Vitamin B12, Vitamin B6, Folic acid

Vitamin B12 tablet

ACTIVE COMPARATOR

1 oral tablet once daily in the morning. Totally 28 tablets at approximately the same time each day through 4 week treatment period

Drug: Vitamin B12 (Cyanocobalamin)

Interventions

Vitamin B12, Vitamin B6, Folic acid DRUG

A solution for intramuscular injection of fixed vitamin combination (5 mg vitamin B6, 1 mg B12 and 1,05 mg folic acid )

Also known as: Medivitan® iM

Vitamin injection

Vitamin B12 (Cyanocobalamin) DRUG

oral tablets of 1mg Vitamin B12

Also known as: B12 Ankermann®

Vitamin B12 tablet

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of written informed consent to participate in the study (according to Order of the Ministry of Health of Ukraine No. 690 (with amendments)).
• Female and male patients aged ≥18.
• Vitamin B12 deficiency, defined as serum vitamin B12 \< 350 pmol/L.
• Female patients of childbearing potential (WOCBP) must be using two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc., with the exception of oral contraceptives), from the time of screening and for the duration of the study, through study completion and for 1 month following study completion. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Female patients who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing. Surgical sterilization procedures should be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF. All female patients of childbearing potential must have negative pregnancy test results at screening. An additional pregnancy test will be performed on Days 0, 28, 56.
• Able to communicate well with the investigator and able to understand and comply with the requirements of the study.
• Patients are otherwise in relatively good health as determined by past medical history, physical examination, vital signs, and laboratory tests at screening (V -1).

You may not qualify if:

• Active or recent vitamin B12, folic acid, B6 intake (the subject must not receive vitamin B12, folic acid, B6 drugs or food supplements for at least 6 months).
• Participation in a previous clinical study with vitamin B12 within the 6 months prior to screening.
• Any contraindication to one of the study drugs.
• Pregnant or nursing (lactating) women.
• Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
• Subjects with anemia (hemoglobin \< 10 mg/dL) or significant neurological symptoms due to vitamin B12 deficiency.
• Any diseases that prevent intrinsic-factor independent passive diffusion in the small intestine (e.g. ileum resection)
• Current drug addiction and/or alcohol abuse as evidenced by patient history and/or as determined by the investigator at V-1.
• Cognitive or behavioural abnormalities that could impair the capacity to give informed consent or carry out protocol-specified procedures.
• Inability to take oral medication.
• Inability or unwillingness to comply with the study protocol.
• Previous (last 6 months) or current participation in another clinical study.
• Other medical, neuropsychiatric, or social conditions that, in the opinion of the investigator, are likely to adversely affect the risk-benefit of study participation, interfere with study compliance, or confound the study results.
• Subjects who are in a dependent relationship with the Investigator or the Sponsor.
• Subjects unwilling to give written informed consent to saving and/or propagation of anonymised medical data

Sponsors & Collaborators

• Medice Arzneimittel Pütter GmbH & Co KG: lead

Study Sites (2)

State institution "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine"

Kharkiv, 61002, Ukraine

RECRUITING

Private Enterprise Private Manufacturing Company "Acinus"

Kropyvnytskyi, 25006, Ukraine

RECRUITING

Related Publications (8)

• Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-76. doi: 10.1159/000376585. Epub 2015 Mar 28.

  PMID: 25831962 BACKGROUND

• Naurath HJ, Riezler R, Putter S, Ubbink JB. Does a single vitamin B-supplementation induce functional vitamin B-deficiency? Clin Chem Lab Med. 2001 Aug;39(8):768-71. doi: 10.1515/CCLM.2001.128.

  PMID: 11592449 BACKGROUND

• Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest. 1996 Jul 1;98(1):177-84. doi: 10.1172/JCI118763.

  PMID: 8690790 BACKGROUND

• Fedosov SN, Brito A, Miller JW, Green R, Allen LH. Combined indicator of vitamin B12 status: modification for missing biomarkers and folate status and recommendations for revised cut-points. Clin Chem Lab Med. 2015 Jul;53(8):1215-25. doi: 10.1515/cclm-2014-0818.

  PMID: 25720072 BACKGROUND

• Metaxas C, Mathis D, Jeger C, Hersberger KE, Arnet I, Walter P. Early biomarker response and patient preferences to oral and intramuscular vitamin B12 substitution in primary care: a randomised parallel-group trial. Swiss Med Wkly. 2017 Apr 7;147:w14421. doi: 10.4414/smw.2017.14421. eCollection 2017.

  PMID: 28421567 BACKGROUND

• Smith AD, Warren MJ, Refsum H. Vitamin B12. Adv Food Nutr Res. 2018;83:215-279. doi: 10.1016/bs.afnr.2017.11.005. Epub 2018 Feb 2.

  PMID: 29477223 BACKGROUND

• Conzade R, Koenig W, Heier M, Schneider A, Grill E, Peters A, Thorand B. Prevalence and Predictors of Subclinical Micronutrient Deficiency in German Older Adults: Results from the Population-Based KORA-Age Study. Nutrients. 2017 Nov 23;9(12):1276. doi: 10.3390/nu9121276.

  PMID: 29168737 BACKGROUND

• 1. Vitamin B12 (Cobalamine). Referenzwerte für die Nährstoffzufuhr. Bonn, Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung, Schweizerische Gesellschaft für Ernährung (Hrsg.). 4. Aktualisierte Ausgabe 2018.

  BACKGROUND

MeSH Terms

Conditions

Vitamin B 12 Deficiency

Interventions

Vitamin B 12; Vitamin B 6; Folic Acid

Condition Hierarchy (Ancestors)

Vitamin B Deficiency; Avitaminosis; Deficiency Diseases; Malnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Corrinoids; Tetrapyrroles; Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Macrocyclic Compounds; Polycyclic Compounds; Picolines; Pyridines; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring

Central Study Contacts

Igor Zupanets, Prof.Dr.

CONTACT

+380679093809; igorzupanets@gmail.com

Tetyana Kolodyezna, PhD

CONTACT

+380937387790; kolodeznaya@aisconsulting.com.ua

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is a Phase IV, randomized, open label, controlled, multicenter, two parallel-group study in female and male patients with vitamin B12 deficiency, to assess the efficacy and safety of two different application routes of vitamin B12.

Study Record Dates

• First Submitted: May 1, 2025
• First Posted: June 19, 2025
• Study Start: April 16, 2025
• Primary Completion: December 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: June 19, 2025

Record last verified: 2025-05

Locations

UA (2)